WEKO3
アイテム
{"_buckets": {"deposit": "c01b4cc2-06eb-42a5-bd6d-2e8db1ca8c7e"}, "_deposit": {"created_by": 3, "id": "2780", "owners": [3], "pid": {"revision_id": 0, "type": "depid", "value": "2780"}, "status": "published"}, "_oai": {"id": "oai:air.repo.nii.ac.jp:00002780", "sets": ["1090"]}, "author_link": ["10234", "10229", "10235", "10228", "10232", "10230", "10238", "10239", "10237", "10226", "10240", "10241", "10231", "10233", "10227", "10236"], "item_10001_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2016-06-30", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "37", "bibliographicPageStart": "29", "bibliographicVolumeNumber": "43", "bibliographic_titles": [{"bibliographic_title": "秋田医学"}]}]}, "item_10001_description_5": {"attribute_name": "内容記述(抄録)", "attribute_value_mlt": [{"subitem_description": "AIM : To compare the efficacy and safety of triple therapy with simeprevir (SMV) against triple\ntherapy with telaprevir (TPV) while treating chronic hepatitis C (CHC).\nMETHOD : A total of 230 CHC patients were enrolled in the present study. One hundred\nforty-three patients were treated with TPV, and 87 patients were treated with SMV. Univariate\nanalyses were performed to evaluate the pretreatment factors contributing to a sustained virological\nresponse at 24 weeks after the end of treatment (SVR24) and adverse events in the TPV and\nSMV groups.\nRESULT : The SVR24 rates in the TPV and SMV groups were 81.1% and 76.8%, respectively.\nThe difference was not statistically significant. In the TPV group, the rates of anemia, nausea\nand renal dysfunction were significantly higher than those in the SMV group.\nCONCLUSION : In the present study, the SVR24 rates achieved by the two therapies did not\ndiffer to a statistically significant extent. However, the rates of some adverse events in the TPV\ngroup were significantly higher than those in the SMV group. SMV was associated with low risk\nand a high SVR24 rate in patients with HCV.", "subitem_description_type": "Other"}]}, "item_10001_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "秋田医学会"}]}, "item_10001_source_id_11": {"attribute_name": "NCID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00009294", "subitem_source_identifier_type": "NCID"}]}, "item_10001_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "03866106", "subitem_source_identifier_type": "ISSN"}]}, "item_10001_version_type_20": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "ARATA, Suguru"}], "nameIdentifiers": [{"nameIdentifier": "10226", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "OHSHIMA, Shigetoshi"}], "nameIdentifiers": [{"nameIdentifier": "10227", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "GOTO, Takashi"}], "nameIdentifiers": [{"nameIdentifier": "10228", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "MIURA, Kouichi"}], "nameIdentifiers": [{"nameIdentifier": "10229", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "KOMATSU, Masafumi"}], "nameIdentifiers": [{"nameIdentifier": "10230", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "NAKANE, Kunio"}], "nameIdentifiers": [{"nameIdentifier": "10231", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "YAGISAWA, Hitoshi"}], "nameIdentifiers": [{"nameIdentifier": "10232", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "TAWARAYA, Hironobu"}], "nameIdentifiers": [{"nameIdentifier": "10233", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "NAKAJIMA, Kou"}], "nameIdentifiers": [{"nameIdentifier": "10234", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "FUNAOKA, Masato"}], "nameIdentifiers": [{"nameIdentifier": "10235", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "HOSHINO, Takao"}], "nameIdentifiers": [{"nameIdentifier": "10236", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "KURAMITSU, Tomoyuki"}], "nameIdentifiers": [{"nameIdentifier": "10237", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "FUJISHIMA, Yuukou"}], "nameIdentifiers": [{"nameIdentifier": "10238", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "WATANABE, Daisuke"}], "nameIdentifiers": [{"nameIdentifier": "10239", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "AJIMINE, Takuma"}], "nameIdentifiers": [{"nameIdentifier": "10240", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "OHNISHI, Hirohide"}], "nameIdentifiers": [{"nameIdentifier": "10241", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2017-02-16"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "akitai43-1(29).pdf", "filesize": [{"value": "839.1 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 839100.0, "url": {"label": "akitai43-1(29).pdf", "url": "https://air.repo.nii.ac.jp/record/2780/files/akitai43-1(29).pdf"}, "version_id": "2ee38b45-88f8-4a3b-b477-324e552a3a4a"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "hepatitis C virus", "subitem_subject_scheme": "Other"}, {"subitem_subject": "interferon", "subitem_subject_scheme": "Other"}, {"subitem_subject": "ribavirin", "subitem_subject_scheme": "Other"}, {"subitem_subject": "telaprevir", "subitem_subject_scheme": "Other"}, {"subitem_subject": "simeprevir", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "A COMPARISON OF THE EFFICACY AND SAFETY OF TREATMENT WITH SIMEPREVIR AGAINST TELAPREVIR", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "A COMPARISON OF THE EFFICACY AND SAFETY OF TREATMENT WITH SIMEPREVIR AGAINST TELAPREVIR"}]}, "item_type_id": "10001", "owner": "3", "path": ["1090"], "permalink_uri": "http://hdl.handle.net/10295/3145", "pubdate": {"attribute_name": "公開日", "attribute_value": "2016-08-12"}, "publish_date": "2016-08-12", "publish_status": "0", "recid": "2780", "relation": {}, "relation_version_is_last": true, "title": ["A COMPARISON OF THE EFFICACY AND SAFETY OF TREATMENT WITH SIMEPREVIR AGAINST TELAPREVIR"], "weko_shared_id": 3}
A COMPARISON OF THE EFFICACY AND SAFETY OF TREATMENT WITH SIMEPREVIR AGAINST TELAPREVIR
http://hdl.handle.net/10295/3145
http://hdl.handle.net/10295/31452cc85f25-0299-407d-bc36-da6fe807b6f1
名前 / ファイル | ライセンス | アクション |
---|---|---|
akitai43-1(29).pdf (839.1 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2016-08-12 | |||||
タイトル | ||||||
タイトル | A COMPARISON OF THE EFFICACY AND SAFETY OF TREATMENT WITH SIMEPREVIR AGAINST TELAPREVIR | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | hepatitis C virus | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | interferon | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | ribavirin | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | telaprevir | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | simeprevir | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
ARATA, Suguru
× ARATA, Suguru× OHSHIMA, Shigetoshi× GOTO, Takashi× MIURA, Kouichi× KOMATSU, Masafumi× NAKANE, Kunio× YAGISAWA, Hitoshi× TAWARAYA, Hironobu× NAKAJIMA, Kou× FUNAOKA, Masato× HOSHINO, Takao× KURAMITSU, Tomoyuki× FUJISHIMA, Yuukou× WATANABE, Daisuke× AJIMINE, Takuma× OHNISHI, Hirohide |
|||||
内容記述(抄録) | ||||||
内容記述タイプ | Other | |||||
内容記述 | AIM : To compare the efficacy and safety of triple therapy with simeprevir (SMV) against triple therapy with telaprevir (TPV) while treating chronic hepatitis C (CHC). METHOD : A total of 230 CHC patients were enrolled in the present study. One hundred forty-three patients were treated with TPV, and 87 patients were treated with SMV. Univariate analyses were performed to evaluate the pretreatment factors contributing to a sustained virological response at 24 weeks after the end of treatment (SVR24) and adverse events in the TPV and SMV groups. RESULT : The SVR24 rates in the TPV and SMV groups were 81.1% and 76.8%, respectively. The difference was not statistically significant. In the TPV group, the rates of anemia, nausea and renal dysfunction were significantly higher than those in the SMV group. CONCLUSION : In the present study, the SVR24 rates achieved by the two therapies did not differ to a statistically significant extent. However, the rates of some adverse events in the TPV group were significantly higher than those in the SMV group. SMV was associated with low risk and a high SVR24 rate in patients with HCV. |
|||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
書誌情報 |
秋田医学 巻 43, 号 1, p. 29-37, 発行日 2016-06-30 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 03866106 | |||||
NCID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AN00009294 | |||||
出版者 | ||||||
出版者 | 秋田医学会 |